1

Poeck, K., Hacke, W.: Multiple Sklerose In: Neurology, 10. Auflage, Springer-Verlag Berlin (1998), S. 499-509

2

Alosi, F., Ria, F., Adorini, L: Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes Immunol. Today (2000)21: 141-147

3

Antel, J. R, Owens, T.: Immune regulation and CNS autoimmune disease J. Neuroimmunol. (1999) 100: 181-189

4

Stinissen, R, Medaer, R., Raus, J.: Myelin reactive T cells in the autoimmune pathogenesis of multiple sclerosis Multiple Sclerosis (1998) 4: 203-211

5

Becher, B., Prat, A., Antel, J. A.: Brain-immune connection: immuno-regulatory properties of CNS-resident cells Glia (2000) 29: 293-304

6

Storch, M. K., Piddlesden, S., Haltia, M. et al.: Multiple sclerosis: in situ evidence for antibody- and complementmediated demyelination Ann. Neurol. (1998) 43: 465-471

7

Hartung, H.-R, Archelos, J. J., Zielasek, J. et al.: Circulating adhesion molecules and inflammatory mediators in demyelination: a review Neurology (1995) 45 (Suppl. 6): S22-S32

8

Bar-Or, A., Oliveira, E. M. L, Anderson, D. E., Hafler, D. A.: Molecular pathogenesis of multiple sclerosis J. Neuroimmunol. (1999) 100: 252-259

9

Ransohoff, R. M.: Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines J. Neuroimmunol. (1999) 98: 57-68

10

Lee, S. J., Benveniste, E. N.: Adhesion molecule expression and regulation on cells of the central nervous System J. Neuroimmunol. (1999) 98: 77-88

11

Kerlero de Rosbo, N., Ben-Nun, A.: T-cell response to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein J. Autoimmunity (1998) 11: 287-299

12

Juedes, A. E., Hjelmström, R, Bergman, C. M. et al.: Kinetics and cellular origin of cytokines in the central nervous System: insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis J. Immunol. (2000) 164: 419-426

13

Zhang, G. X., Baker, C. M., Kolson, D. L, Rostami, A. M.: Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis Multiple Sclerosis (2000) 6:3-13

14

Heesen, C, Sieverding, F., Buhmann, C. et al.: IL-1ra serum levels in disease stages of MS - a marker for progression? Acta Neurol. Scand. (2000) 101: 95-97

15

Huang, Y.-M., Xiao, B.-G., Özenci, V. et al.: Multiple sclerosis is associated with high levels of circulating dendriticcells secreting pro-inflammatory cytokines J. Neuroimmunol. (1999) 99: 82-90

16

Bitsch, A., Kuhlmann, T., Da Costa, C. et al.: Tumour necrosis factor alpha mRNS expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology Glia (2000) 29: 366-375

17

Cpnlon, R, Oksenberg, J. R., Zhang, J., Steinman, L: The immunobiology of multiple sclerosis: an autoimmunedisease of the central nervous System Neurobiol. Dis. (1999) 6: 149-166

18

Ferguson, B., Matyszak, M. K., Esiri, M. M., Perry, V. H.: Axonal damage in acute multiple sclerosis lesions Brain (1997) 120: 393-399

19

Bjartmar, C., Yin, X., Trapp, B. D.: Axonal pathology in myelin disorders J. Neurocytol. (1999) 28: 383-395

20

Lassmann, H., Brück, W., Lucchinetti, C., Rodriguez, M.: Remyelination in multiple sclerosis Multiple Sclerosis (1997) 3: 133-136

21

Wolswijk, G.: Oligodendrocyte precursor cells in chronic multiple sclerosis lesions Multiple Sclerosis (1997) 3: 168-169

22

Lucchinetti, C., Brück, W., Paris!, J. et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination Ann. Neurol. (2000)47: 707-717

23

Archelos, J. J., Storch, M. K., Härtung, H.-R: The role of B cells and autoantibodies in multiple sclerosis Ann. Neurol. (2000) 47: 694-7

24

Elkarim, R.A., Mustafa, M., Kivisäkk, P. Et al.: Cytokine autoantibodies in multiple sclerosis, aseptic meningitisand stroke Eur. J. Clin. Invest. (1998) 28: 295-299

25

Genain, C. P., Canella, B., Hauser, S. L, Raine, C. S.: Identification of autoantibodies associated with myelin damage in multiple sclerosis NatureMed. (1999)5: 170-175

26

Spadaro, M., Amendolea, M. A., Mazzucconi, M. G. et al.: Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies Multiple Sclerosis (1999) 5: 121-125

27

Heckl, R. W.: Multiple Sklerose. Diagnose und Differentialdiagnose anhand klinischer Symptome Therapiewoche (1996) 7: 372-375

28

Heckl, R. W.: Erstsymptome erkennen und richtig werten Landarztpraxis (1997) 7/8: 310-314

29

Thompson, A. J., McDonald, W.I.: Multiple sclerosis and its pathophysiology. In: Diseases of the nervous System, Asbury, A.K., McKhann, G.M., McDonald, W.l. (eds.), Philadelphia: W. B. Saunders Co. (1992), pp. 1209-1228

30

Hassan-Zahraee, M., Ladiwala, U., Lavoie, P. M. et al.: Superantigen presenting capacity of human astrocytes J. Neuroimmunol. (2000) 102: 131-136

31

Torres, B. A., Johnson, H. M.: Modulation of disease by superantigens Curr. Opinion Immunol. (1998)10:465-470

32

Collawn, J. F., Benveniste, E. N.: Regulation of MHC class II expression in the central nervous System Microbes Infection (1999) 1: 893-902

33

Droogan, A. G., McMillain, S. A., Dougkas, J. R, Hawkins, S. A.: Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1 J. Neuroimmunol. (1996) 64: 185-191

34

Khoury, S. J., Orav, E. J., Guttmann, C. R. G. et al.: Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis Neurology (1999) 53:758-764

35

Elovaara, I., Ukkonen, M., Leppäkynnäs, M. et al.: Adhesion molecules in multiple sclerosis Arch. Neurol. (2000) 57: 546-551

36

Poser, C. M., Paty, D. W., Scheinberg, L. et al.: New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann. Neurol. (1983) 13: 227-231

37

Kurtzke, J. F.: Rating neurologic impairment in multiple sclerosis: an expanded disability Status scale (EDSS) Neurology (1983) 33: 1444-1452

38

De Stefano, N., Matthews, P. M., Fu, L. et al.: Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study Brain(1998) 121: 1469-1477

39

McGavern, D. B., Murray, P. D., Rivera-Quinones, C. et al.: Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis Brain (2000) 123: 519-531

40

Stevenson, V., L, Leary, S. M., Losseff, N. A. et al.: Spinal cord atrophy and disability in MS. A longitudinal study Neurology (1998) 51: 234-238

41

Bodis, L, Szupera, Z., Pierantozzi, M. et al.: Neurological complications of pregnancy J. Neurol. Sei. (1998) 153: 279-293

42

Confavreux, C, Hutchinson, M., Hours, M. M. et al.: Rate of pregnancy-related relapse in multiple sclerosis N. Engl. J. Med. (1998) 339: 285-291

43

Van Walderveen, M. A. A., Tas, M. W., Barkhof, F. et al.: Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis Neurology (1994) 44: 327-329

44

Nait-Oumesmar, B., Lachapelle, F., Decker, L, Baron-Van Evercooren, A.: Do central nervous System axons remyelinate? Pathol. Biol. (2000) 48: 70-70

45

Compston, A.: Remyelination in multiple sclerosis: a challage for therapy. The 1996 European Charcot Foundation Lecture Multiple Sclerosis (1997) 3: 51-70

46

Lucchinetti, C. F., Noseworthy, J. H., Rodriguez, M.: Promotion of endogenous remyelination in multiple sclerosis Multiple Sclerosis (1997) 3: 71-75

47

Pöhlau, D., Atkas, O., Epplen, C. et al.: Remyelinisierungsförderung als zukünftiges Therapieprinzip der Multiplen Sklerose? Nervenarzt (1998) 69: 841-850

48

Asakura, K., Rodriguez, M.: A unique population of circulating autoantibodies promotes central nervous System remyelination Multiple Sclerosis (1998) 4:217-221

49

Seifert, J.: IgM - Gegenstand aktueller klinischer Forschung Krankenhauspharmazie (1988) 9: 17-20

50

Bjornson, A. B., Detmers, P. A.: The pentameric structure of IgM is necessary to enhance opsonization of bacteroides thetaiotaomicron and bacteroides fragilis via the alternative complement pathway Microb. Pathog. (1995) 19:117-128

51

Hurez, V., Kazatchkine, M. D., Vassilev, T. et al.: Pooled normal human polyspecific IgM contains neutralizing antiidiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease Blood (1997) 90: 4004-4013

52

Kaveri, V., Kazatchkine, M. D., Vassilev, T.: Autoimmunität an der Grenze zur Autoaggression Aspekte im Gespräch (1996) 4: 9-17

53

Mouthon, L., Lacroix-Desmazes, S., Nobregat, A. et al.: The self-reactive antibody repertoire of normal human serum IgG is acquired in early childhood and remains conserved throughout life Scand. J. Immunol. (1996) 44: 243-251

54

Ehrenstein, M. R., Cook, H. T., Neuberger, M. S.: Deficiency in serum immunoglobulin (lg)M predisposes to development of IgG autoantibodies J. Exp. Med. (2000) 191: 1253-1257

55

Rodriguez, M., Miller, D. J., Lennon, V. A.: Immunoglobulins reactive with myelin basic protein promote CNS remyelination Neurology (1996) 46: 538-545

56

van Schalk, I. N., Vermeulen, M„ Brand, A.: Immunomodulation and remyelination: two aspects of human polyclonal immunoglobulin treatment in immune mediated neuropathies? Multiple Sclerosis (1997) 3: 98-104

57

Kuhlmann, T., Brück, W.: Immunoglobulins induce increased myelin debris clearance by macrophages Multiple Sclerosis (1999) S (Suppl.1): 25

58

Stangel, M., Compston, A., Scolding, N. J.: Polyclonal immunoglobulins for intravenous use do not influence the behavior of cultured oligodendrocytes J.Neuroimmunol. (.1999) 96:228-233

59

Dalakas, M. C: Mechanism of action of intravenous immunoglobulin and therapeutic coniderations in the treatment of autoimmune neurologic diseases Neurology (1998) 51 (Suppl. 5): S2-S8

60

Rieben, R., Roos, A., Muizert, Y. et al.: Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation Blood (1999) 93: 942-951

61

Stangel, M., Comptson, A., Scolding, N. J.: Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins (IVIG) J. Neuroimmunol. (2000) 103: 195-201

62

Webster, H. F.: Growth factors and myelin regeneration in multiple sclerosis Multiple Sclerosis (1997) 3: 113-120

63

Vignais, L, Nait-Oumesmar, B., Gout, O. et al.: Migration and differentation of transplanted oligodendrocyte precursors in the adult demyelinated mouse spinal cord Int. J. Dev. Neurosci. (1993) 11: 603-612

64

Blakermore, W., Franklin, R. J. M.: Transplantation of glial cells in CNS Trends Neurosci. 14: 323-327

65

Kieseier, B. C., Archelos, J. J., Storch, M. et al.: The immunopathogenesis of multiple sclerosis. A survey of recent advances and implications for future therapy Wien.Klin. Wochenschr. (1999) 111: 728-737

66

Rudick, R. A., Cohen, J. A., Weinstock-Guttman, B. et al.: Management of multiple sclerosis N. Engl. J. Med. (1997) 337: 1604-1610

67

Bashir, K., Whitaker, J. N.: Current immunotherapy in multiple sclerosis Immunol. Cell Biol. (1998) 76: 55-64

68

Multiple Sklerose-Therapie Konsensus Gruppe (MSTKG): Immunmodulatorische Stufentherapie der   multiplen Sklerose Nervenarzt (1999) 70: 371-386

69

Arnason, B. G. W.: Immunologie therapy of multiple sclerosis Annu. Rev. Med. (1999) 50: 291-302

70

Smith, P. F., Darlington, C. L: Recent developments in drug therapy for multiple sclerosis Multiple Sclerosis (1999) 5: 110-120

71

Baumhackl, U., Härtung, H.-R, Ladumer, G.: 3. Multiple-Sklerose-Konsensuskonferenz Neuropsychiatrie (2000)14:40-54

72

Andersson, P.-B., Goodkin, D. E.: Glucocorticosteroid therapy for multiple sclerosis: a critical review J. Neurol. Sei. (1998) 160: 16-25

73

Bereznai, B., Goebels, T., Dang, R, et al.: Therapie der multiplen Sklerose Dtsch. med. Wschr. (1999) 124: 595-599

74

Oliveri, R. L., Valentine, P., Russo, C. et al.: Randomized trial comparing two different high doses of methylprednisolone in MS. A clinical and MRI study Neurology (1998) 50: 1833-1836

75

Sellebjerg, F., Frederiksen, J. L, Nielsen, P. M., lesen, J.: Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS Neurology (1998) 51: 529-534

76

Wandinger, K. P., Wessel, K., Trillenberg, P. et al.: Effect of high-dose methylprednisolone administration on immune functions in multiple sclerosis patients Acta Neurol. Sei. (1998) 97: 359-365

77

Goodkin, D. E., Bailly, R. C., Teetzen, M. L. et al.: The efficacy of azathioprine in relapsing-remitting multiple sclerosis Neurology (1991) 41:20-26

78

Yudkin, P., Ellison, G. W., Ghezzi, A. et al.: Overview of azathioprine treatment in multiple sclerosis Lancet (1991) 338: 1051-1055

79

Hartung, H.-P, Kieseier, B.: Targets for therapeutic action of interferon-beta in multiple sclerosis Ann. Neurol. (1996) 40: 824-825

80

Milo, R., Panitch, H.: Glatiramer acetate or interferon-ß for multiple sclerosis CNSDrugs (1999) 11: 289-306

81

IFN-ß Multiple Sclerosis Study Group: Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial Neurology (1995) 45: 1277-1285

82

Jacobs, L. D., Cookfair, D. L, Rudick, R. A. et al.: Intramuscular-interferon beta-1a for disease progression in relapsing multiple sclerosis Ann. Neurol. (1996) 39: 285-294

83

PRISMS Study Group: Randomized double-blind placebo-controlled study of interferon-ß1 a in relapsing/remitting multiple sclerosis Lancet (1998) 352: 1498-1504

84

OWIMS Study Group: Interferon beta-1a in multiple sclerosis: dose-dependent clinical and MRI efficacy In: 123. Ann. Meeting Am. Neurol. Assoc. (1998), Montreal, abstract

85

European Study Group on Interferon beta-1b in Secondary Progressive MS, Kappos, L., Miller, D. et al.: Placebo-controlled multicentre randomised trial of Interferon ß-1b in treatment of secondary progressive multiple sclerosis Lancet (1998) 352: 1491-1497

86

Paty, D.W. and the Secondary Progressive Interferon beta-1a MS Study Group: Results of the 3-year, doubleblind, placebo-controlled study of Interferon beta-1a (Rebif®) in secondary-progressive MS J. Neurol. (1999) 246: (Suppl. 1), 1/15

87

Miller, A., Shapiro, S., Gershtein, R. et al.: Treatment of multiple sclerosis with copolymer-1 (Copaxone®): implicating mechanisms of Th1 to Th2/Th3 immune deviation J. Neuroimmunol. (1998)92:113-121

88

Mancardi, G. L, Sardanelli, F., Parodi, R. C. et al.: Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis Neurology (1998) 50: 1127-1133

89

La Mantia, L., Milanese, C, Damico, R.: Meta-analysis of clinical trials with copolymer-1 in multiple sclerosis Eur. Neurol. (2000)43: 189-193

90

Duda, P. W., Schmied, M. C., Cook, S. L. et al.: Glatiramer acetate (Copaxone,) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis J. Clin. Invest. (2000) 105: 967-976

91

Rieckmann, R, Toyka, K. V. and the Austrian-German-Swiss Multiple Sclerosis Therapy Consensus Group (MSTCG): Escalating immunotherapy of multiple sclerosis Eur. Neurol. (1999)42: 121-127

92

Millefiorini, E., Gasperini, C, Pozzilli, C. et al.: Randomized placebo-controlled trial of mitoxantrone in relapsing remitting multiple sclerosis: 24-month clinical and MRI outcome J. Neurol. (1997)244: 153-159

93

Hartung, H.-R, Gonsette, R. and the   MIMS-Study Group: Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind European phase III multicenter srudy - clinical results Multiple Sclerosis (1998) 4: 325 (Abstract)

94

Koehler, J., Beer, K., Pette, M.: Mitoxantron-Therapie bei Multipler Sklerose Akt. Neurol. (1998)25: 1-3

95

Mauch, E.: Neueste Studien zu modernen Immunsuppressiva Klinikarzt (1999) 28: 200-203                                                          

96

Burt, R., Brenner, M, Burns, W. et al.: Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease J. Clin. Immunol. (2000) 20: 1-9

97

Fassas, A., Anagnostopoulos, A., Kazis, A. et al.: Autologous stem cell transplantation in progressive multiple sclerosis - an Interim analysis of efficacy J. Clin. Immunol. (2000) 20: 24-30

98

Stangel, M., Hartung, H.-R, Marx, P. Gold, R.: Intravenous immunoglobulin treatment of neurologica diseases J. Neurol. Sei. (1998) 153: 203-214

99

Hahn, A. F.: Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin Neurology (1998) 51(Suppl. 5): S22-S24

100

Dalakas, M. C: Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis Neurology (1998) 51 (Suppl. 5): S37-S45

101

Howard, J. F.: Intravenous immunoglobulin for the treatment of acquired myasthenia gravis Neurology (1998) 51 (Suppl. 5): S30-S36

102

Sater, R. A., Rostami, A.: Treatment of Guillain-Barrö syndrome with intravenous immunoglobulin Neurology (1998) 51 (Suppl. 5): S9-S15

103

Lisak, R. R: Intravenous immunoglobulins in multiple sclerosis Neurology (1998) 51 (Suppl. 5): S25-S29

104

Kaveri, S., Prasad, N., Vassilev, T. et al.: Modulation of autoimmune responses by intravenous immunoglobulin (MG) Multiple Sclerosis (1997 3: 121-128

105

Zipp, F., Atkas, O.: Spezielle Aspekte von Immunpathogenese urid Reparaturvorgängen bei Multipler Sklerose - mögliche Rolle von intravenösen Immunglobulinen In: Immunmodulation mit Immunglobulinen bei Autoimmunerkrankungen und Infektionen, M.G. Kühl, W. P. Naß, H.-D. Volk (Hrsg.), Stuttgart: Georg Thieme Verlag, (2000), S. 70-79

106

Stangel, M., Joly, E., Scolding, N. J., Comptson, D. A. S.: Normal polyclonal immunoglobulins (IVIG) inhibit microglial phagocytosis in vitro J. Neuroimmunol. (2000) 106: 137-144

107

Gesicherte Indikationen in der Behandlung mit intravenösen Immunglobulinen in der Neurologie Nervenarzt (2000) 71: Beilage, S. 4-12

108

Fazekas, F., Deisenhammer, F., Strasser-Fuchs, S. et al.: Randomized placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis Lancet (1997) 349: 589-593

109

Fazekas, F., Deisenhammer, F., Strasser-Fuchs, S. et al.: Treatment effects of monthly intravenous Immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian immunoglobulin in MS study Multiple Sclerosis (1997) 3: 137-141

110

Fazekas, F., Strasser-Fuchs, S., Härtung, H.-R: Intravenöse Immunglobuline in der Therapie der schubförmigen multiplen Sklerose - Ein Update Nervenarzt (1998)69:361-365

111

Achiron, A., Gabbay, U., Gilad, R. et al.: Intravenous immunoglobulin treatment in multiple sclerosis. Effect onrelapses Neurology (1998) 50: 398-402

112

Soelberg-Sorensen, R, Wanscher, B., Schreiber, K. et al.: A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results Multiple Scierosis (1997)3: 145-148

113

Schuller, E., Lambin, R, Deloche, G.: Long-term treatment of multiple sclerosis with IgG immunotherapy Path. Biol. (1996) 44: 710-71 5

114

Stangel, M., Borgner, F., Klatt, C. H. et al.: Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis  J. Neurol. Neurosurg. Psychiatry (2000) 68: 89-92

115

Weinshenker, B. G., Bass, B., Rice, G. P. A. et al.: The natural history of multiple sclerosis: a geographical based study Brain (1980) 10: 1090-1091

116

Confavreux, C., Aimard, G., Devic, M.: Course and prognosis of multiple sclerosis assessed by computerized data processing of 349 patients Brain (1980) 103: 281-300

117

Cook, S. D. Troiano, R., Rohowsky-Kochin, C. et al.: Intravenous gamma globulin in progressive MS Acta Neurol. Scand. (1992) 86: 171-175

118

Kalanie, H., Tabatabai, S. S.: Combined immunoglobulin and azathioprine in multiple sclerosis Eur. Neurol. (1998)39: 178-181

119

Mauch, E.: MG bei mitoxantronresistenter Multipler Sklerose In: Immunmodulation mit Immunglobulinen bei Autoimmunerkrankungen und Infektionen, M. G. Kühl, W. P. Naß, H.-D. Volk (Hrsg), Stuttgart: Georg Thieme Verlag (2000) S. 80-82

120

Francis G. S., Freedman, M. S., Antel, J. R: Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study Multiple Sclerosis (1997) 3: 370-376

121

Solberg-Scrensen, R, Wanscher, B., Jensen, C. V. et al.: Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis Neurology (1998)50: 1273-1281

122

Achiron, A., Rotstein, 2., Noy, S. et al.: Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study J. Neurol. (1996)243:25-28

123

Haas, J. (nicht publizierte Daten): Vortrag auf dem 15th Congress of the Eur. Committee and for Treatment and Research in MS (ECTRIMS), Basel, September 1999

124

Rothfelder, U., Neu, I., Pelka, R.: Therapie der multiplen Sklerose mit Immunglobulin G Münch. med. Wschr. (1982) 124: 74-78

125

Soukop, W., Tschabitscher, H.: Gammaglobulintherapie bei Multipler Sklerose (MS) Wiener med. Wochenschr. (1986) 18: 477-480

126

Achiron, A., Präs, E., Gilad, R. et al.: Open controlled therapeutic trial of intravenous immune globulin in relapsing remitting multiple sclerosis Arch. Neurol. (1992) 49: 1233-1236

127

Haas, J., Stark, E., Wurster, U. et al.: Doppelblind geführte kontrollierte Studie zur Wirksamkeit von Immunglobulin 7S im Schub der Multiplen Sklerose Verh. DGN (1992) 7: 41 1

128

Yan, J., Kichert, J. R., Sirdofsky, M. D.: High-dose intravenous immunoglobulin for multiple sclerosis Lancet (1990) 336: 692

129

van Engelen, B. G. M., Hommers, O. R., Pinckers, A. et al.: Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis Ann. Neurol. (1992) 32: 834-835

130

Kleiman, M., Brunquell, R: Acute disseminated encephalomyelitis: response to intravenous immunoglobulin? J. Child. Neurol. (1995) 10: 481-483

131

Hahn, J. S., Siegler.D. J., Enzmann, D.: Intravenous gammaglobulin therapy in recurrent acute disseminated encephalomyelitis Neurology (1996) 46: 1173-1174

132

Assa, A., Watemberg, N., Bujanover, Y. et al.: Demyelinative brainstem encephalitis responsive to intravenous mmunoglobulin therapy Pediatrics (1999) 104: 301-304

133

Pradhan, S., Gupta, S. R, Shashank, S., Pandey, N.: Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis J. Neurol. Sei. (1999)165:56-61

134

Nishikawa, M., Ichiyama, T., Hayashi, T. et al.: Intravenous immunoglobulin therapy in acute disseminated. encephalomyelitis Pediatr. Neurol. (1999) 21: 583-586